Travere Therapeutics Share Price (NASDAQ: TVTX)

$17.49

▲

-0.21

(-1.19%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Travere Therapeutics Stock chart to analyse performance

Travere Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$17.45
Today's High:$17.88
$17.49
0.23%
Downside
Day's Volatility :2.4%
Upside
2.18%
52 Weeks Low:$9.34
52 Weeks High:$25.29
$17.49
46.6%
Downside
52 Weeks Volatility :63.07%
Upside
30.84%

Travere Therapeutics Stock Returns

Period	Travere Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	12.66%	3.6%	0.0%
6 Months	-11.69%	-7.7%	0.0%
1 Year	82.14%	-12.6%	0.0%
3 Years	-37.69%	9.5%	-4.7%

Travere Therapeutics Inc Key Stats

Check Travere Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$17.7
Open	$17.7
Today's High	$17.88
Today's Low	$17.45
Market Capitalization	$1.6B
Today's Volume	$2.0M
52 Week High	$25.29
52 Week Low	$9.34
Revenue TTM	$333.9M
EBITDA	$-120.5M
Earnings Per Share (EPS)	$-2.02
Profit Margin	-50.64%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-705.73%

Stock Returns calculator for Travere Therapeutics Stock including INR - Dollar returns

The Travere Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Travere Therapeutics investment value today

Current value as on today

₹1,89,973

Returns

₹89,973

(+89.97%)

Returns from Travere Therapeutics Stock

₹84,688 (+84.69%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Travere Therapeutics Stock

800%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Travere Therapeutics Stock from India on INDmoney has increased by 800% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Travere Therapeutics Inc

Name
Holdings %
Name
Holdings %
HHG PLC
10.70%
Armistice Capital, LLC
9.96%
BlackRock Inc
9.19%
Vanguard Group Inc
6.72%
Macquarie Group Ltd
5.38%
State Street Corp
4.09%

Analyst Recommendation on Travere Therapeutics Stock

Rating

Trend

Buy

72%Buy

27%Hold

0%Sell

Based on 22 Wall street analysts offering stock ratings for Travere Therapeutics(by analysts ranked 0 to 5 stars)

Travere Therapeutics Share Price Target

What analysts predicted

Upside of 104.2%

Target:

$35.71

Current:

$17.49

Travere Therapeutics share price target is $35.71, a slight Upside of 104.2% compared to current price of $17.49 as per analysts' prediction.

Travere Therapeutics Stock Insights

Price Movement
In the last 1 year, TVTX stock has moved up by 84.6%
Increasing Revenue
Revenue is up for the last 6 quarters, 41.37M → 114.44M (in $), with an average increase of 18.1% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -60.26M → -12.75M (in $), with an average increase of 134.7% per quarter
TVTX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 146.3%

Travere Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$175.3M	↑ 6.75%
Net Income	$-146.4M	↑ 42.61%
Net Profit Margin	-83.51%	↓ 21.0%

	FY20	Y/Y Change
Revenue	$198.3M	↑ 13.11%
Net Income	$-169.4M	↑ 15.71%
Net Profit Margin	-85.43%	↓ 1.92%

	FY21	Y/Y Change
Revenue	$227.5M	↑ 14.71%
Net Income	$-180.1M	↑ 6.29%
Net Profit Margin	-79.16%	↑ 6.27%

	FY22	Y/Y Change
Revenue	$212.0M	↓ 6.8%
Net Income	$-278.5M	↑ 54.63%
Net Profit Margin	-131.35%	↓ 52.19%

	FY23	Y/Y Change
Revenue	$145.2M	↓ 31.5%
Net Income	$-111.4M	↓ 60.0%
Net Profit Margin	-76.7%	↑ 54.65%

	FY24	Y/Y Change
Revenue	$233.2M	↑ 60.55%
Net Income	$-321.5M	↑ 188.64%
Net Profit Margin	-137.9%	↓ 61.2%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$41.4M	↓ 8.18%
Net Income	$-136.1M	↑ 50.89%
Net Profit Margin	-328.86%	↓ 128.74%

	Q2 FY24	Q/Q Change
Revenue	$54.1M	↑ 30.8%
Net Income	$-70.4M	↓ 48.25%
Net Profit Margin	-130.11%	↑ 198.75%

	Q3 FY24	Q/Q Change
Revenue	$62.9M	↑ 16.23%
Net Income	$-54.8M	↓ 22.15%
Net Profit Margin	-87.14%	↑ 42.97%

	Q4 FY24	Q/Q Change
Revenue	$74.8M	↑ 18.9%
Net Income	$-60.3M	↑ 9.95%
Net Profit Margin	-80.58%	↑ 6.56%

	Q1 FY25	Q/Q Change
Revenue	$81.7M	↑ 9.29%
Net Income	$-41.2M	↓ 31.59%
Net Profit Margin	-50.44%	↑ 30.14%

	Q2 FY25	Q/Q Change
Revenue	$114.4M	↑ 40.03%
Net Income	$-12.8M	↓ 69.06%
Net Profit Margin	-11.14%	↑ 39.3%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$170.1M	↑ 7.17%

	FY20	Y/Y Change
Profit	$192.2M	↑ 12.99%

	FY21	Y/Y Change
Profit	$220.7M	↑ 14.83%

	FY22	Y/Y Change
Profit	$204.4M	↓ 7.38%

	FY23	Y/Y Change
Profit	$133.8M	↓ 34.55%

	FY24	Y/Y Change
Profit	$225.4M	↑ 68.5%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$39.9M	↑ 39.2%

	Q2 FY24	Q/Q Change
Profit	$41.7M	↑ 4.61%

	Q3 FY24	Q/Q Change
Profit	$61.3M	↑ 46.9%

	Q4 FY24	Q/Q Change
Profit	$72.2M	↑ 17.89%

	Q1 FY25	Q/Q Change
Profit	$77.1M	↑ 6.67%

	Q2 FY25	Q/Q Change
Profit	$98.9M	↑ 28.37%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-58.2M	↑ 133.25%
Investing Cash Flow	$19.9M	↓ 109.77%
Financing Cash Flow	$-2.1M	↓ 100.9%

	FY20	Y/Y Change
Operating Cash Flow	$-42.7M	↓ 26.58%
Investing Cash Flow	$-61.3M	↓ 408.75%
Financing Cash Flow	$127.7M	↓ 6248.92%

	FY21	Y/Y Change
Operating Cash Flow	$-14.8M	↓ 65.39%
Investing Cash Flow	$-137.6M	↑ 124.41%
Financing Cash Flow	$231.7M	↑ 81.41%

	FY22	Y/Y Change
Operating Cash Flow	$-186.3M	↑ 1159.4%
Investing Cash Flow	$-32.6M	↓ 76.35%
Financing Cash Flow	$117.6M	↓ 49.25%

	FY23	Y/Y Change
Operating Cash Flow	$-280.0M	↑ 50.31%
Investing Cash Flow	$55.8M	↓ 271.34%
Financing Cash Flow	$218.8M	↑ 86.06%

	FY24	Y/Y Change
Operating Cash Flow	$-237.5M	↓ 15.19%
Investing Cash Flow	$99.3M	↑ 78.08%
Financing Cash Flow	$139.4M	↓ 36.26%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-119.0M	↑ 68.87%
Investing Cash Flow	$104.9M	↓ 718.87%
Financing Cash Flow	$-525.0K	↓ 523.39%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-40.2M	↓ 66.18%
Investing Cash Flow	$28.6M	↓ 72.73%
Financing Cash Flow	$782.0K	↓ 248.95%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-42.5M	↑ 5.63%
Investing Cash Flow	$46.1M	↑ 61.22%
Financing Cash Flow	$46.0K	↓ 94.12%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-35.7M	↓ 15.97%
Investing Cash Flow	$-80.3M	↓ 274.11%
Financing Cash Flow	$139.1M	↑ 302332.61%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-42.2M	↑ 18.12%
Investing Cash Flow	$41.3M	↓ 151.41%
Financing Cash Flow	$3.7M	↓ 97.33%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$5.0M	↓ 111.81%
Investing Cash Flow	$4.9M	↓ 88.25%
Financing Cash Flow	$1.5M	↓ 60.33%

Travere Therapeutics Technicals Summary

Sell

Neutral

Buy

Travere Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Travere Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Travere Therapeutics Inc	13.17%	-11.69%	82.14%	-37.69%	-6.35%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Travere Therapeutics Inc	NA	NA	NA	-0.28	-7.06	-0.19	NA	0.37
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Travere Therapeutics Inc	Buy	$1.6B	-6.35%	NA	-50.64%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Organization	Travere Therapeutics
Employees	385
CEO	Dr. Eric M. Dube Ph.D.
Industry	Health Technology

Key Management of Travere Therapeutics Inc

Name	Title
Dr. Eric M. Dube Ph.D.	President, CEO & Director
Mr. Christopher Cline C.F.A.	Chief Financial Officer
Dr. William E. Rote Ph.D.	Chief Research Officer
Mr. Peter Heerma	Chief Commercial Officer
Dr. Jula Inrig M.D.	Chief Medical Officer
Ms. Sandra Calvin	SVP, Corporate Controller & Chief Accounting Officer
Ms. Nivi Nehra	Vice President of Corporate Communications & Investor Relations
Ms. Elizabeth E. Reed J.D.	Chief Legal Officer, General Counsel & Secretary
Ms. Angela Giannantonio	Chief People Officer
Mr. Casey Logan	Chief Business Officer

Important FAQs about investing in TVTX Stock from India :

What is Travere Therapeutics share price today?

Travere Therapeutics share price today is $17.49 as on August 30, 2025 at 1:29 am IST at the close of the market. Travere Therapeutics share today touched a day high of $17.88 and a low of $17.45.

What is the 52 week high and 52 week low for Travere Therapeutics share?

Travere Therapeutics share touched a 52 week high of $25.29 and a 52 week low of $9.34. Travere Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $17.49, lower by 30.84% versus the 52 week high.

How to invest in Travere Therapeutics Stock (TVTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Travere Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Travere Therapeutics Shares that will get you 0.0858 shares as per Travere Therapeutics share price of $17.49 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Travere Therapeutics Stock (TVTX) from India?

Indian investors can start investing in Travere Therapeutics (TVTX) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Travere Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Travere Therapeutics share’s latest price of $17.49 as on August 30, 2025 at 1:29 am IST, you will get 0.5718 shares of Travere Therapeutics. Learn more about fractional shares .

What are the returns that Travere Therapeutics has given to Indian investors in the last 5 years?

Travere Therapeutics stock has given -6.35% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?